Show simple item record

dc.contributor.authorGordon, LI
dc.contributor.authorKaplan, B
dc.contributor.authorPopat, R
dc.contributor.authorBurris, HA
dc.contributor.authorFerrari, S
dc.contributor.authorMadan, S
dc.contributor.authorPatel, MR
dc.contributor.authorGritti, G
dc.contributor.authorEl-Sharkawi, D
dc.contributor.authorChau, I
dc.contributor.authorRadford, John A
dc.contributor.authorPerez, de Oteyza, J
dc.contributor.authorLuigi, Zinzani, P
dc.contributor.authorIyer, S
dc.contributor.authorTownsend, W
dc.contributor.authorKarmali, R
dc.contributor.authorMiao, H
dc.contributor.authorProscurshim, I
dc.contributor.authorWang, S
dc.contributor.authorWu, Y
dc.contributor.authorStumpo, K
dc.contributor.authorShou, Y
dc.contributor.authorCarpio, C
dc.contributor.authorBosch, F
dc.date.accessioned2020-06-15T12:57:37Z
dc.date.available2020-06-15T12:57:37Z
dc.date.issued2020en
dc.identifier.citationGordon LI, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, et al. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma. Clin Cancer Res. 2020.en
dc.identifier.pmid32327472en
dc.identifier.doi10.1158/1078-0432.ccr-19-3239en
dc.identifier.urihttp://hdl.handle.net/10541/622962
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1158/1078-0432.ccr-19-3239en
dc.titlePhase I study of TAK-659, an investigational, dual SYK/FLT3 iinhibitor, in patients with B-cell lymphomaen
dc.typeArticleen
dc.contributor.departmentMedicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Centeren
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record